Captopril
Active ingredient description
Captopril is a highly specific, competitive inhibitor of angiotensin-I converting enzyme (ACE inhibitors). Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. In patients with hypertension, captopril causes a reduction in supine and erect blood pressure, without inducing any compensatory increase in heart rate, nor water and sodium retention.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Medicines
Captopril is the active ingredient of these drugs:
Ireland
Cyprus
Tunisia
Brazil
Hong Kong
South Africa
Brazil
Tunisia
Australia New Zealand
Brazil
Brazil
Hong Kong Tunisia
Germany
Germany
Brazil
Lithuania South Africa
Brazil
Hong Kong
Brazil
Brazil
Brazil
Spain
Brazil
Singapore
Tunisia
Singapore
Cyprus Hong Kong Singapore
Brazil
Tunisia
Turkey
Tunisia
Tunisia
Turkey
France United Kingdom
Brazil
Cyprus Hong Kong
South Africa
Tunisia
Brazil
South Africa
Captopril is also found within below combination drugs:
ACTOZID , CAPTOGAMMA HCT , CAPTORETIC , CAPTOZID , CAPTRAL ASA , CO-TENSOPRIL , DILABAR DIU , ECAZIDE , SUPERACE , ZAPTO-CO
Structural formula
Chemical formula: C₉H₁₅NO₃S
Molecular mass: 217.285 g/mol
3D molecular structure